Lithuania

 

New AI act could stifle EU innovation – but benefit the UK

After 38 hours of deliberation, a long-awaited deal has finally been reached in Brussels. HBI speaks to three market experts to understand what the AI Act - the comprehensive European framework for AI innovation and regulation - could mean for the future of healthcare in Europe.
December 15, 2023

iCON buys Alliance Medical

The longstanding bidding war for pan-European diagnostic firm Alliance Medical Group is over, with iCON Infrastructure confirmed as the new buyer. The £910m deal ends months of speculation. HBI asks a UK-based consultant what this means for the market.
October 13, 2023

Alliance Medical sale “imminent”

HBI hears that the longstanding sale of UK diagnostic firm Alliance Medical Group is imminent, with two bidders left in the process and pan-European operator Affidea tipped to be the front-runner. We speak to three market experts to find out more about the deal which is being valued at around $800m-$1bn.
September 22, 2023

HBI 2023: The outpatient differential

For years there has been a trend towards using outpatient services wherever possible - to improve patient outcomes, to better use an increasingly scarce workforce, and to increase cost efficiency. On the “Outpatient differential” panel at HBI 2023, how this push looks across the world was a key topic for discussion.
July 12, 2023

Mubadala-backed M42 buying Diaverum “for $2bn+”

Swedish multinational dialysis firm Diaverum is being bought by M42, a joint venture between Abu Dhabi sovereign wealth fund Mubadala Investment Co and AI firm G42, for a reported $2bn-$2.5bn. Diaverum’s CEO tells HBI the deal offers further opportunities to develop its digital strategies, and international expansion. 
April 19, 2023

Diaverum deal: An analysis

Last week the news broke that Abu Dhabi sovereign wealth fund Mubadala Investment Co might be set to buy Swedish multinational dialysis firm Diaverum for a reported $2.5bn. HBI speaks to an operator source who thinks this would be a good price for the seller - and hears why some investors are switched off by dialysis.
April 6, 2023

Cinven looks to take Synlab private as Covid boost falters

Frankfurt-listed Synlab could be about to be taken private following a non-binding full takeover offer earlier this week. With its full year results released yesterday and facing questions about its plans, HBI asks market experts what they think of the move.
March 17, 2023

Affidea deal – underbidders and EBITDA

HBI hears that the surprise buyer of European imaging and cancer treatment provider Affidea, Groupe Bruxelles Lambert (GBL) may not have been the highest bidder, despite winning out. HBI considers who else was in the running, and the EBITDA figure that may have been used for the deal.
April 28, 2022
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us